Simba Gill, CEO of Evelo Biosciences
While down 87% YOY, Evelo gets Flagship and others to infuse new capital for comeback hope
Just four years after Flagship spinout Evelo Biosciences went public in an IPO worth $85 million, the biotech has seen its share price tank from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
